Search Within

Virginia Klimek

Formats
  1. Meeting Abstract (78)
  2. Journal Article (64)
  3. Editorial (2)
  4. Research Letter (2)
  5. Book Section (1)
Groups
  1. Adult Leukemia (147)
  2. Center for Hematologic Malignancies (147)
  3. Department of Medicine (147)
  4. Hematologic Malignancies, Division of (147)
  5. GSK Faculty (44)
  6. Epidemiology and Biostatistics (36)

More Groups

People
  1. Stephen Nimer (30)
  2. Sean Devlin (26)
  3. Martin Tallman (22)
  4. Ross Levine (21)
  5. Stephen Chung (18)
  6. Elli Papaemmanuil (14)

More People

Years
  1. 2024 (2)
  2. 2023 (4)
  3. 2022 (3)
  4. 2021 (5)
  5. 2020 (8)
  6. 2019 (14)

More Years

Publications
  1. Blood (54)
  2. Leukemia Research (10)
  3. Journal of Clinical Oncology (9)
  4. Haematologica (8)
  5. Bone Marrow Transplantation (4)
  6. British Journal of Haematology (3)

More Publications

Publishers
  1. American Society of Hematology (54)
  2. Nature Publishing Group (17)
  3. American Society of Clinical Oncology (10)
  4. Elsevier Ltd (10)
  5. Ferrata Storti Foundation (8)
  6. American Association for Cancer Research (6)

More Publishers

Results (147)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Doxorubicin and dexamethasone followed by thalidomide and dexamethasone (AD-TD) as initial therapy for symptomatic patients with multiple myeloma
    Meeting Abstract

    Hassoun, H.; Reich, L.; Klimek, V. M.; Kewalramani, T.; Dhodapkar, M.; Drake, L.; Zimman, R.; Hedvat, C. V.; Teruya-Feldstein, J.; Fleisher, M.; more...
    Blood (2004)

    Fulltext@MSK | Save
  • Unbalanced translocations are frequently detected in patients with treatment-related myelodysplastic syndromes and acute leukemia
    Meeting Abstract

    Klimek, V. M.; Schreiber, D.; Merrell, J.; Nimer, S. D.; Jhanwar, S. C.
    Blood (2003)

    Fulltext@MSK | Save
  • A phase II study of stem cell mobilization with IV melphalan (60 mg/M-2) + G-CSF in multiple myeloma
    Meeting Abstract

    Gupta, S.; Costello, S.; Zhou, P.; Reich, L.; Hassoun, H.; Klimek, V.; Kewalramani, T.; Dhodapkar, M.; Fleisher, M.; Hedvat, C.; more...
    Blood (2003)

    Fulltext@MSK | Save
  • A randomized phase II trial of the tyrosine kinase inhibitor PKC412 in patients (pts) with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS) characterized by wild-type (WT) or mutated FLT3
    Meeting Abstract

    Estey, E. H.; Fisher, T.; Giles, F.; Feldman, E. J.; Ehninger, G.; Schiller, G. J.; Klimek, V. M.; Nimer, S. D.; De Angelo, D. J.; Gilliland, D. G.; more...
    Blood (2003)

    Fulltext@MSK | Save
  • Doxorubicin and dexamethasone (AD) followed by thalidomide and dexamethasone (TD) as initial therapy for symptomatic patients with multiple myeloma
    Meeting Abstract

    Comenzo, R. L.; Hassoun, H.; Reich, L.; Klimek, V.; Kewalramani, T.; Dhodapkar, M.; Drake, L.; Hedvat, C.; Teruya-Feldstein, J.; Fleisher, M.; more...
    Blood (2003)

    Fulltext@MSK | Save
  • Severe and selective deficiency of interferon-γ-producing invariant natural killer T cells in patients with myelodysplastic syndromes
    Journal Article

    Fujii, S. I.; Shimizu, K.; Klimek, V.; Geller, M. D.; Nimer, S. D.; Dhodapkar, M. V.
    British Journal of Haematology (2003)

    Fulltext@MSK | Save
  • Results of autologous stem cell transplantation (SCT) following stem cell mobilization with melphalan in myeloma patients
    Meeting Abstract

    Comenzo, R. L.; Costello, S.; Reich, L.; Drake, L.; Zhou, P.; Martinez, C.; Klimek, V.; Kewalramani, T.; Osman, K.; Dhodapkar, M.; more...
    Blood (2002)

    Fulltext@MSK | Save
  • PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): A phase II clinical trial
    Meeting Abstract

    Stone, R. M.; Klimek, V.; DeAngelo, D. J.; Nimer, S.; Estey, E.; Galinsky, I.; Neuberg, D.; Yap, A.; Fox, E. A.; Gilliland, D. G.; more...
    Blood (2002)

    Fulltext@MSK | Save
  • T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: Randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants
    Journal Article

    Schaed, S. G.; Klimek, V. M.; Panageas, K. S.; Musselli, C. M.; Butterworth, L.; Hwu, W. J.; Livingston, P. O.; Williams, L.; Lewis, J. J.; Houghton, A. N.; more...
    Clinical Cancer Research (2002)

    Fulltext@MSK | Save
  • Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients
    Journal Article

    Klimek, V. M.; Williams, L.; Chapman, P. B.
    Cytokines Cellular and Molecular Therapy (2002)

    Fulltext@MSK | Save